<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Cross-sectional studies found less <z:mp ids='MP_0002959'>microalbuminuria</z:mp> in type 2 diabetic patients with the Ala12 allele of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) Pro12Ala polymorphism </plain></SENT>
<SENT sid="1" pm="."><plain>We prospectively evaluated the association between Pro12Ala polymorphism (rs1801282) and new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Pro12Ala polymorphism was genotyped by TaqMan-based assay in genomic DNA of 1,119 consenting patients from BErgamo NEphrologic DIabetic Complications Trial (BENEDICT)-a prospective, randomized trial evaluating ACE inhibition effect on new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (<z:mp ids='MP_0002871'>albuminuria</z:mp> 20-200 microg/min in at least two of three consecutive overnight urine collections in two consecutive visits) in hypertensive type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with <z:mp ids='MP_0002871'>albuminuria</z:mp> &lt;20 microg/min at inclusion </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Baseline characteristics of Ala (Ala/Ala or Ala/Pro) carriers and Pro/Pro homozygotes were similar, with a nonsignificant trend to lower <z:mp ids='MP_0002871'>albuminuria</z:mp> (P = 0.1107) in the 177 Ala carriers </plain></SENT>
<SENT sid="4" pm="."><plain>Over a median (interquartile range) of 44.0 (17.1-51.9) months, 7 (4%) Ala carriers and 86 (9.1%) Pro/Pro homozygotes developed <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (hazard ratio [HR] 0.45 [95% CI 0.21-0.97]; P = 0.042) </plain></SENT>
<SENT sid="5" pm="."><plain>Final <z:mp ids='MP_0002871'>albuminuria</z:mp> was significantly lower in Ala carriers than Pro/Pro homozygotes (7.3 +/- 9.1 vs. 10.5 +/- 24.9 microg/min, respectively), even after adjustment for baseline <z:mp ids='MP_0002871'>albuminuria</z:mp> (P = 0.048) </plain></SENT>
<SENT sid="6" pm="."><plain>Baseline and follow-up blood pressure and metabolic control were similar in both groups </plain></SENT>
<SENT sid="7" pm="."><plain>Incidence of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> was significantly decreased by ACE versus non-<z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> therapy in Pro/Pro homozygotes (6.3 vs. 11.9%, respectively, HR 0.46 [0.29-0.72]; P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the Ala allele protects from worsening <z:mp ids='MP_0002871'>albuminuria</z:mp> and new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002959'>microalbuminuria</z:mp>, and ACE inhibition blunts the excess risk of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> associated with the Pro/Pro genotype </plain></SENT>
<SENT sid="9" pm="."><plain>Evaluating Pro12Ala polymorphism may help identifying patients at risk who may benefit the most from early renoprotective therapy </plain></SENT>
</text></document>